1. Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance
62 Day Standard Performance
Q1 2019/20
Sunita Berry/Patricia McLarnon

2. Cancer Waiting Times Indicator
CWTs June 2019 Q1 2019
NHS England
Cancer Waiting Times Indicator
Seen within 2 weeks of referral
Seen within 2 weeks. Referred for breast symptoms
Treated within 31 Days from decision to treat to first treatment
Treated within 31 Days where subsequent treatment was anti-cancer drug
Treated within 31 Days where subsequent treatment was radiotherapy
Treated within 31 Days where subsequent treatment was surgery
Treated within 62 Days from referral to first treatment (including rare cancers)
Treated within 62 Days from national screening to first treatment
Treated within 62 Days from consultant upgrade to first treatment
England
89.9%
75.5%
96.3%
98.9%
96.7%
91.2%
79.4%
89.7%
84.1%
England (incl. Wales LHB)
East of England
90.1%
76.1%
96.5%
96.4%
84.5%
79.7%
86.6%
London
93.0%
90.4%
97.4%
99.3%
98.0%
95.8%
81.9%
90.5%
89.8%
Midlands
87.1%
65.8%
95.6%
99.0%
75.8%
91.1%
82.1%
North East and Yorkshire
88.2%
69.7%
98.1%
92.1%
80.1%
90.6%
North West
64.9%
97.6%
99.6%
98.5%
96.2%
80.7%
90.3%
85.8%
South East
93.3%
86.9%
99.4%
94.4%
79.6%
85.1%
81.8%
South West
85.9%
72.3%
94.8%
95.5%
80.3%
84.9%

4. Jun-19 Seen within target
SWAG CWTs June 2019
Measure
Standard
Jun-19 Performance
Jun-19 Number Seen
Jun-19 Seen within target
Jun-19 Breaches
18-19 Q1 Performance
19-20 Q1 Performance
Two week wait from cancer referral to specialist appointment
93%
88.6%
10,349.0
9,170.0
1,179.0
91.3%
88.4%
Two week wait (breast symptoms - cancer not suspected)
89.6%
528.0
473.0
55.0
89.9%
91.4%
31-day wait from decision to treat to first treatment
96%
94.0%
1,294.0
1,217.0
77.0
96.7%
94.6%
31-day wait for subsequent surgery
94%
88.2%
272.0
240.0
32.0
95.0%
89.8%
31-day wait for subsequent anti-cancer drug regimen
98%
99.3%
282.0
280.0
2.0
98.8%
31-day wait for subsequent radiotherapy
322.0
294.0
28.0
95.5%
94.5%
62-day wait from referral to treatment (including rare cancers)
85%
74.9%
733.0
549.0
184.0
81.4%
79.0%
Screening:
Breast
90%
92.5%
93.0
86.0
7.0
95.8%
94.4%
Gynaecological
85.7%
6.0
1.0
83.3%
93.3%
Lower Gastrointestinal
77.8%
18.0
14.0
4.0
76.2%
85.1%
62-day wait for treatment following a referral from a screening service
118.0
106.0
12.0
92.3%
93.0%
62-day wait for treatment following a consultant upgrade
n/a
78.1%
192.0
150.0
42.0
81.2%
83.9%

5. Times Series Treated within 62 Days

6. Jun-19 Seen within target
62 day by tumour type
Tumour Type
Jun-19 Performance
Jun-19 Number Seen
Jun-19 Seen within target
Jun-19 Breaches
Jun day waits
18-19 Q1 Performance
19-20 Q1 Performance
Brain/Central Nervous System -
100.0%
Breast
90.6% 96 87 9
96.2%
92.6%
Gynaecological
75.6% 41 31 10 3
84.0%
75.7%
Haematological (Excluding Acute Leukaemia)
64.3% 42 27 15 5
77.5%
70.5%
Head & Neck
50.0% 26 13 1
67.1%
57.0%
Lower Gastrointestinal
62.3% 69 43
67.2%
69.3%
Lung
60.3% 63 38 25 2
66.7%
67.9%
Other
75.0% 8 6
83.8%
80.0%
Sarcoma 4
92.9%
68.4%
Skin
96.9%
162
157
96.8%
98.1%
Upper Gastrointestinal
80.4% 51
80.2%
82.4%
Urological (Excluding Testicular)
59.4%
165 98 67
66.3%
61.1%
Acute leukaemia
Children's
Testicular
Total
74.9%
733
549
184
81.4%
79.0%